Buy Cipla and sell GAIL at current levels, says Sudarshan Sukhani, s2analytics.com.
Sukhani told CNBC-TV18, "Cipla has not done what it should have done given the chart correction, the base building that it went through. But then there is a sense that maybe it's getting ready for a fairly decent move on the upside. Cipla is a buying opportunity. Our targets are Rs 342- 345. But the theme is that pharma broadly is to be bought into."
He further added, "GAIL is going to slip more. So GAIL is a short sell. You look at Rs 365. A lot of these stocks were in consolidation and then slowly have started breaking down one after the other and a lot of them are PSUs. But in any case GAIL is not looking good. It has broken the significant Rs 400 level. I think it is going much lower."
